<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Regulatory risk on FinanClub</title>
    <link>https://finan.club/tags/regulatory-risk/</link>
    <description>Recent content in Regulatory risk on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 11 Mar 2024 09:03:54 +0000</lastBuildDate><atom:link href="https://finan.club/tags/regulatory-risk/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>TGTX</title>
      <link>https://finan.club/us/tgtx/</link>
      <pubDate>Mon, 11 Mar 2024 09:03:54 +0000</pubDate>
      
      <guid>https://finan.club/us/tgtx/</guid>
      <description>score:113
Chances: TG Therapeutics, Inc. has announced the presentation of data from the ULTIMATE I &amp;amp; II Phase 3 trials evaluating BRIUMVIÂ® in patients with relapsing forms of multiple sclerosis, indicating potential positive outcomes from the trials. The company has reported strong financial results, with BRIUMVI U.</description>
    </item>
    
    <item>
      <title>GOTU</title>
      <link>https://finan.club/us/gotu/</link>
      <pubDate>Wed, 28 Feb 2024 09:05:45 +0000</pubDate>
      
      <guid>https://finan.club/us/gotu/</guid>
      <description>score:51
Chances: Gaotu Techedu Inc. continues to demonstrate strong financial performance, with impressive unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Risks: The company operates in a highly competitive market, with potential risks from regulatory changes and shifts in consumer behavior.</description>
    </item>
    
  </channel>
</rss>
